Co-diagnostics jv cosara receives clearance from indian regulators for abc multiplex test

Salt lake city, dec. 7, 2021 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) (the "company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that cosara diagnostics pvt ltd ("cosara," or the "jv"), its joint venture for manufacturing and sales in india, has received clearance by the central drugs standard control organization ("cdsco") in india to manufacture and sell its saraplex™ flu a/flu b/covid-19 (abc) rt-pcr test as an in vitro diagnostic ("ivd"). cosara's new test, the 4th cosara assay to receive cdsco approval this year and 11th overall, is built on the company's patented coprimer™ technology and designed for the simultaneous detection and differentiation of influenza a, influenza b, and sars-cov-2.
CODX Ratings Summary
CODX Quant Ranking